VanEck Associates’s GW Pharmaceuticals Plc American Depositary Shares GWPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-18,047
| Closed | -$3.91M | – | 1330 |
|
|
2021
Q1 | $3.91M | Sell |
18,047
-3,086
| -15% | -$580K | 0.01% | 478 |
|
|
2020
Q4 | $2.44M | Sell |
21,133
-2,841
| -12% | -$318K | 0.01% | 505 |
|
|
2020
Q3 | $2.33M | Sell |
23,974
-8,146
| -25% | -$937K | 0.01% | 451 |
|
|
2020
Q2 | $3.94M | Buy |
32,120
+2,900
| +10% | +$329K | 0.01% | 369 |
|
|
2020
Q1 | $2.56M | Buy |
29,220
+7,117
| +32% | +$754K | 0.01% | 409 |
|
|
2019
Q4 | $2.31M | Buy |
22,103
+4,065
| +23% | +$456K | 0.01% | 497 |
|
|
2019
Q3 | $2.08M | Sell |
18,038
-13,512
| -43% | -$2.05M | 0.01% | 477 |
|
|
2019
Q2 | $5.44M | Buy |
31,550
+1,602
| +5% | +$277K | 0.03% | 324 |
|
|
2019
Q1 | $5.05M | Sell |
29,948
-17,447
| -37% | -$2.6M | 0.02% | 301 |
|
|
2018
Q4 | $4.62M | Buy |
47,395
+8,568
| +22% | +$1.12M | 0.02% | 318 |
|
|
2018
Q3 | $6.71M | Sell |
38,827
-8,319
| -18% | -$1.2M | 0.03% | 281 |
|
|
2018
Q2 | $6.58M | Buy |
47,146
+5,094
| +12% | +$724K | 0.03% | 266 |
|
|
2018
Q1 | $4.74M | Buy |
42,052
+4,969
| +13% | +$625K | 0.02% | 300 |
|
|
2017
Q4 | $4.89M | Sell |
37,083
-260
| -0.7% | -$30.6K | 0.02% | 285 |
|
|
2017
Q3 | $3.79M | Buy |
37,343
+16,003
| +75% | +$1.71M | 0.02% | 322 |
|
|
2017
Q2 | $2.14M | Sell |
21,340
-8,217
| -28% | -$884K | 0.01% | 391 |
|
|
2017
Q1 | $3.58M | Buy |
29,557
+18,169
| +160% | +$2.23M | 0.02% | 340 |
|
|
2016
Q4 | $1.27M | Sell |
11,388
-12,874
| -53% | -$1.55M | 0.01% | 452 |
|
|
2016
Q3 | $3.22M | Buy |
+24,262
| New | +$2.32M | 0.02% | 339 |
|
Other funds holding GWPH
VanEck Associates's GWPH Position: Q2 2021 in Review
VanEck Associates sold out of GW Pharmaceuticals Plc American Depositary Shares (GWPH) in Q2 2021, closing a stake of 18,047 shares — an estimated $3.91M sold.
VanEck Associates first reported a position in GWPH in Q3 2016 and held it in 19 quarters. The position peaked at $6.71M in Q3 2018. 1 fund tracked by Wall St. Rank holds GWPH as of Q2 2021.
- VanEck Associates reported no remaining GW Pharmaceuticals Plc American Depositary Shares position as of Q2 2021 after selling out during the quarter.
- VanEck Associates sold 18,047 GW Pharmaceuticals Plc American Depositary Shares shares in Q2 2021, an estimated $3.91M.
- VanEck Associates first reported a position in GW Pharmaceuticals Plc American Depositary Shares in Q3 2016 and held it in 19 quarters.
- VanEck Associates's GW Pharmaceuticals Plc American Depositary Shares position peaked at $6.71M in Q3 2018.
- 1 fund tracked by Wall St. Rank held GW Pharmaceuticals Plc American Depositary Shares as of Q2 2021.
Based on VanEck Associates's 13F filing for Q2 2021, filed 10 Aug 2021.